Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer

Suresh Ramalingam, MD


Suresh Ramalingam, MD, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, discussed results from the phase 3 LAURA study. Results demonstrated that  administration of osimertinib after definitive chemoradiation improved progression-free survival (PFS) among patients with unresectable, stage 3, EGFR-mutated non-small cell lung cancer (NSCLC).


Source:

Ramalingam SS. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract LBA4

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement